|
Hetero Drugs exploring in biosimlars; to launch more products on commercial scale soon
|
|
Our Bureau, Hyderabad
February 10 , 2017
|
|
|
Hetero Drugs, one of the largest generic pharmaceutical manufacturing
companies in India, has now started exploring the biosimilars market and
has already launched three products in the last two years.
Hetero
Drugs has become the leader in the supply of antiretroviral (ARV) drugs
across the global, and now its ventures into biosimilars is gaining the
company many successes. “One out of every three patients across the
globe is using ARV supplied from Hetero Drugs and it has become one of
the largest exporters ARV medicines across the world. As part of our
expansion plans, Hetero has ventured into biosimilars two years back and
has successfully launched 3 products viz., Darbepoetin Alf-for anaemia
and Chronic Kidney Diseases (CKD), Retuximah—(monoclonal antibody) for
treating blood cancers and Bevacizumab--for treating rheumatoid
arthritis,” informed Ramesh Reddy, marketing manager, International
Biologics Business, at Hetero Labs.
Apart from the above three
products, the company is also having two products in pipeline, which are
still under clinical trial stage and very soon it is also expecting
these products will clear the final clinical trial stage and will be
launched in the market very soon. “We have two more Monoclonal Antibody
(MAB) products in the pipeline which are under various stages of
clinical trial. These include adalimumamb and trastuzumab, once these
products get cleared the clinical trial state we will launch them in the
market,” informed Reddy, while explaining about the company’s new
ventures at BioAsia in Hyderabad.
According to Reddy, the company
has two more products in the pipeline to be launched in market soon in
the next few days and by 2020 it is expecting to launch at least 10 more
products on the commercial scale.
Unlike with generic drugs of
the more common small-molecule type, biologics generally exhibit high
molecular complexity, and may be quite sensitive to changes in
manufacturing processes.
Explaining further, Reddy said that
biosimilars are similar to vaccines, but in vaccines, the inactive
antibodies are extracted from humans to prepare vaccines, while in
biosimilars, the inactive disease causing strains can be extracted from
any source belonging to mammalians.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|